Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model

Antiviral Research

Volumn 104, Issue 1, 2014, Pages 153-155

  Smither, Sophie J ^a   Eastaugh, Lin S ^a   Steward, Jackie A ^a   Nelson, Michelle ^a   Lenk, Robert P ^b   Lever, Mark S ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b MediVector Inc   (United States)

Author keywords

Aerosol; Bioterrorism; Broad spectrum; Ebola; Favipiravir; Licensed

Indexed keywords

FAVIPIRAVIR;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FILOVIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AEROSOL; BIOTERRORISM; BROAD-SPECTRUM; EBOLA; FAVIPIRAVIR; LICENSED;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; MICE; MICE, KNOCKOUT; PYRAZINES;

EID: 84896692632     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.01.012     Document Type: Article

References (19)

1. T. Baranovich, S.S. Wong, J. Armstrong, H. Marjuki, R.J. Webby, R.G. Webster, and E.A. Govorkova T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro J. Virol. 87 2013 3741 3751
2. M. Bray The role of the Type I interferon response in the resistance of mice to filovirus infection J. Gen. Virol. 82 2001 1365 1373 (Pubitemid 32519767)
3. M. Bray Defense against filoviruses used as biological weapons Antiviral Res. 57 2003 53 60 (Pubitemid 36254721)
4. B.M. Friedrich, J.C. Trefry, J.E. Biggins, L.E. Hensley, A.N. Honko, D.R. Smith, and G.G. Olinger Potential vaccines and post-exposure treatments for filovirus infections Viruses 4 2012 1619 1650
5. Y. Furuta, K. Takahashi, Y. Fukuda, M. Kuno, T. Kamiyama, K. Kozaki, N. Nomura, H. Egawa, S. Minami, Y. Watanabe, H. Narita, and K. Shiraki In vitro and in vivo activities of anti-influenza virus compound T-705 Antimicrob. Agents Chemother. 46 2002 977 981 (Pubitemid 34260339)
6. Y. Furuta, K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, N. Nomura, H. Egawa, and K. Shiraki Mechanism of action of T-705 against influenza virus Antimicrob. Agents Chemother. 49 2005 981 986 (Pubitemid 40327713)
7. Y. Furuta, B.B. Gowen, K. Takahashi, K. Shiraki, D.F. Smee, and D.L. Barnard Favipiravir (T-705), a novel viral RNA polymerase inhibitor Antiviral Res. 100 2013 446 454
8. B.B. Gowen, M.H. Wong, K.H. Jung, A.B. Sanders, M. Mendenhall, K.W. Bailey, Y. Furuta, and R.W. Sidwell In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections Antimicrob. Agents Chemother. 51 2007 3168 3176 (Pubitemid 350067524)
9. Z. Jin, L.K. Smith, V.K. Rajwanshi, B. Kim, and J. Deval The Ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase PLoS One 8 2013 e68347
10. J.G. Julander, D.F. Smee, J.D. Morrey, and Y. Furuta Effect of T-705 treatment on western equine encephalitis in a mouse model Antiviral Res. 82 2009 169 171
11. J.G. Julander, K. Shafer, D.F. Smee, J.D. Morrey, and Y. Furuta Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106 Antimicrob Agents Chemother. 53 2009 202 209
12. M.G. Kortepeter, D.G. Bausch, and M. Bray Basic clinical and laboratory features of filoviral hemorrhagic fever J. Infect. Dis. 204 2011 S810 S816
13. E.K. Leffel, and D.S. Reed Marburg and Ebola viruses as aerosol threats Biosecur. Bioterror. 2 2004 186 191
14. M.S. Lever, T.J. Piercy, J.A. Steward, L. Eastaugh, S.J. Smither, C. Taylor, F.J. Salguero, and R.J. Phillpotts Lethality and pathogenesis of airborne infection with filoviruses in A129 α/β -/- interferon receptor-deficient mice J. Med. Microbiol. 61 2012 8 15
15. M. Mendenhall, A. Russell, D.F. Smee, J.O. Hall, R. Skirpstunas, Y. Furuta, and B.B. Gowen Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever PLoS Negl. Trop. Dis. 5 2011 e1342
16. J.D. Morrey, B.S. Taro, V. Siddharthan, H. Wang, D.F. Smee, A.J. Christensen, and Y. Furuta Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents Antiviral Res. 80 2008 377 379
17. J. Rocha-Pereira, D. Jochmans, K. Dallmeier, P. Leyssen, M.S. Nascimento, and J. Neyts Favipiravir (T-705) inhibits in vitro norovirus replication Biochem. Biophys. Res. Commun. 424 2012 777 780
18. H. Sangawa, T. Komeno, H. Nishikawa, A. Yoshida, K. Takahashi, N. Nomura, and Y. Furuta Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase Antimicrob. Agents Chemother. 57 2013 5202 5208
19. R.W. Sidwell, D.L. Barnard, C.W. Day, D.F. Smee, K.W. Bailey, M.H. Wong, J.D. Morrey, and Y. Furuta Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice Antimicrob. Agents Chemother. 51 2007 845 851 (Pubitemid 46355265)